Sacubitril/valsartan, a pioneering drug in the class of dual CD10 and angiotensin receptor inhibitors (ARNI), has been proven to enhance outcomes for patients with symptomatic HF featuring reduced systolic function, and its use for the treatment of HF was approved by the FDA in 2015 (McMurray et al., 2014; Chen and Burnett, 2017; Khder et al., 2017; Kario, 2018; Pascual-Figal et al., 2021). This evidence concerns the gene MME and hydrops fetalis.